Abstract: The present invention relates to the design of a customized therapy for a subject with breast cancer based on the c-MAF expression level and the menopausal status of the subject. In some embodiments, the customized therapy comprises an agent for avoiding, treating or preventing bone degradation. In some embodiments, the agent for avoiding, treating or preventing bone degradation is zoledronic acid. In other embodiments, the agent is clodronate or denosumab.

Abstract: The present invention relates to the design of a customized therapy for a subject with breast cancer based on the c-MAF expression level and the menopausal status of the subject. In some embodiments, the customized therapy comprises an agent for avoiding or preventing bone degradation. In some embodiments, the agent for avoiding or preventing bone degradation is zoledronic acid.

Abstract: The present invention relates to the design of a customized therapy for a subject with breast cancer based on the c-MAF expression level and the menopausal status of the subject. In some embodiments, the customized therapy comprises an agent for avoiding, treating or preventing bone degradation. In some embodiments, the agent for avoiding, treating or preventing bone degradation is zoledronic acid. In other embodiments, the agent is clodronate or denosumab.

Abstract: The present invention relates to the design of a customized therapy for a subject with breast cancer based on the c-MAF expression level and the menopausal status of the subject. In some embodiments, the customized therapy comprises an agent for avoiding or preventing bone degradation. In some embodiments, the agent for avoiding or preventing bone degradation is zoledronic acid.

Abstract: The present invention relates to the design of a customized therapy for a subject with breast cancer based on the c-MAF expression level and the menopausal status of the subject. In some embodiments, the customized therapy comprises an agent for avoiding, treating or preventing bone degradation. In some embodiments, the agent for avoiding, treating or preventing bone degradation is zoledronic acid. In other embodiments, the agent is clodronate or denosumab.

Abstract: The disclosure relates to binding members, especially antibody molecules, which bind to human Maf. The binding members are useful for the determination of the expression level of Maf.

Abstract: The present invention relates to the design of a customized therapy for a subject with breast cancer based on the c-MAF expression level and the menopausal status of the subject. In some embodiments, the customized therapy comprises an agent for avoiding or preventing bone degradation. In some embodiments, the agent for avoiding or preventing bone degradation is zoledronic acid.

Abstract: In an electronic key system, at least one of an electronic key and a vehicle side device includes a communication device, a storage unit, and a discrimination unit. The storage unit acquires a location information from a location information terminal through the communication device, and stores information on an unlocking permissible range based on the location information when a vehicle door is locked. The discrimination unit acquires the location information from the location information terminal through the communication device, and discriminates whether the acquired location information falls within the unlocking permissible range, or not, when the wireless communication is performed between the electronic key and the vehicle side device because the vehicle door is unlocked. When the discrimination unit discriminates that the position of the electronic key does not fall within the unlocking permissible range, the vehicle door is not unlocked.

Abstract: A communication device includes a communication control unit generating a communication signal to be transmitted to an external source and an encryption unit connected to the communication control unit through a wiring. The communication control unit stores a predetermined communication signal indicative of a predetermined message and a target duration required for from a transmission of the predetermined communication signal to a reception of the same from the encryption unit. The communication control unit further counts an actual duration taken from the transmission of the predetermined communication signal to the reception of the same from the encryption unit. When the actual duration is longer than the target duration, the communication control unit determines that a fraudulent circuit is inserted into the wiring for fraudulently acting on the communication signal.

Abstract: The disclosure relates to binding members, especially antibody molecules, which bind to human Maf. The binding members are useful for the determination of the expression level of Maf.

Abstract: A communication device includes a communication control unit generating a communication signal to be transmitted to an external source and an encryption unit connected to the communication control unit through a wiring. The communication control unit stores a predetermined communication signal indicative of a predetermined message and a target duration required for from a transmission of the predetermined communication signal to a reception of the same from the encryption unit. The communication control unit further counts an actual duration taken from the transmission of the predetermined communication signal to the reception of the same from the encryption unit. When the actual duration is longer than the target duration, the communication control unit determines that a fraudulent circuit is inserted into the wiring for fraudulently acting on the communication signal.

Abstract: In an electronic key system, at least one of an electronic key and a vehicle side device includes a communication device, a storage unit, and a discrimination unit. The storage unit acquires a location information from a location information terminal through the communication device, and stores information on an unlocking permissible range based on the location information when a vehicle door is locked. The discrimination unit acquires the location information from the location information terminal through the communication device, and discriminates whether the acquired location information falls within the unlocking permissible range, or not, when the wireless communication is performed between the electronic key and the vehicle side device because the vehicle door is unlocked. When the discrimination unit discriminates that the position of the electronic key does not fall within the unlocking permissible range, the vehicle door is not unlocked.

Abstract: The present invention relates to the use of ecteinascidin 743 in human patients having certain molecular markers profile which has been associated with the outcome of ET-743 chemotherapy. In particular, the invention relates to the use of ecteinascidin 743 in patients having high expression levels of XPG mRNA or protein and/or having a “wild type” genotype for Asp1104His SNP of XPG gene.

Abstract: The present invention relates to the use of ecteinascidin 743 in patients having certain levels of molecular markers who can predict the outcome of chemotherapy, in particular in patients having low levels of BRCA1 expression.

Abstract: Oligonucleotide is immobilised to a surface using a saccharide or related polymer with at least two different functionalities.